Considering that NF2 loss has been linked with PCa progression and poor prognosis [148], patients with metastatic NF2-deficient CRPC may be included in an ongoing basket clinical trial evaluating a novel TEAD inhibitor (NCT04665206). Here, NF2 is linked to posterior cortical atrophy.